BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol 2019;15:73-86. [DOI: 10.1038/s41581-018-0081-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Chang CP, Su YC, Lin MC, Huang ST. Chinese Herbal Medicine Ameliorated the Development of Chronic Kidney Disease in Patients with Chronic Hepatitis C: A Retrospective Population-Based Cohort Study. Evid Based Complement Alternat Med 2019;2019:5319456. [PMID: 31871483 DOI: 10.1155/2019/5319456] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Gaudêncio M, Nogueira R, Afonso N. Mixed Cryoglobulinaemia Vasculitis after Persistent Hepatitis C Virus Eradication. Eur J Case Rep Intern Med 2021;8:002808. [PMID: 34527630 DOI: 10.12890/2021_002808] [Reference Citation Analysis]
3 Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C. [Chronic kidney injury in patients with liver diseases - Reappraising pathophysiology and treatment options]. Z Gastroenterol 2021;59:560-79. [PMID: 33728618 DOI: 10.1055/a-1402-1502] [Reference Citation Analysis]
4 Devresse A, Delire B, Lazarus JV, Kabamba B, De Meyer M, Mourad M, Buemi A, Darius T, Cambier JF, Goffin E, Jadoul M, Kanaan N. Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era. Transplant Proc 2020;52:815-22. [PMID: 32143864 DOI: 10.1016/j.transproceed.2020.01.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Reference Citation Analysis]
6 Jadoul M, Labriola L, Gordon CE. HCV Can and Should Be Eliminated From Dialysis Units. Am J Kidney Dis 2021;78:487-8. [PMID: 34144101 DOI: 10.1053/j.ajkd.2021.06.001] [Reference Citation Analysis]
7 Chang R, Chen ML, Lin CL, Hung YM, Wei JC. Association of Infection With Human Papillomavirus and Development of End-Stage Kidney Disease in Taiwan. JAMA Netw Open 2020;3:e2022107. [PMID: 33090225 DOI: 10.1001/jamanetworkopen.2020.22107] [Reference Citation Analysis]
8 Awan AA, Jadoul M, Martin P. Hepatitis C in Chronic Kidney Disease: An Overview of the KDIGO Guideline. Clin Gastroenterol Hepatol 2020;18:2158-67. [PMID: 31376491 DOI: 10.1016/j.cgh.2019.07.050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
9 Jalota A, Lindner BK, Thomas B, Lerma EV. Hepatitis C and Treatment in Patients with Chronic Kidney Disease. Dis Mon 2021;67:101017. [PMID: 32553421 DOI: 10.1016/j.disamonth.2020.101017] [Reference Citation Analysis]
10 Wiseman AC. CKD in Recipients of Nonkidney Solid Organ Transplants: A Review. Am J Kidney Dis 2021:S0272-6386(21)01047-7. [PMID: 34979161 DOI: 10.1053/j.ajkd.2021.10.014] [Reference Citation Analysis]
11 Biliotti E, Palazzo D, Tinti F, D'Alessandro MD, Esvan R, Labriola R, Cappoli A, Umbro I, Volpicelli L, Bachetoni A, Villa E, Mitterhofer AP, Rucci P, Taliani G. HCV cirrhotic patients treated with direct-acting antivirals: Detection of tubular dysfunction and resolution after viral clearance. Liver Int 2021;41:158-67. [PMID: 32979012 DOI: 10.1111/liv.14672] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Genes Immun. 2019;20:436-446. [PMID: 31019253 DOI: 10.1038/s41435-019-0066-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
13 Morelli MC, Rendina M, La Manna G, Alessandria C, Pasulo L, Lenci I, Bhoori S, Messa P, Biancone L, Gesualdo L, Russo FP, Petta S, Burra P; Italian Association for the Study of Liver, and the Italian Society of Nephrology. Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). Dig Liver Dis 2021;53 Suppl 2:S49-86. [PMID: 34074490 DOI: 10.1016/j.dld.2021.03.035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Huiban L, Chiriac S, Cuciureanu T, Trifan A. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother 2021;22:1729-41. [PMID: 33896315 DOI: 10.1080/14656566.2021.1921737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Iliescu EL, Mercan-Stanciu A, Toma L. Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. BMC Nephrol 2020;21:21. [PMID: 31948406 DOI: 10.1186/s12882-020-1687-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Abaalkhail F, Al-hamoudi W, Altraif I, Mohamed H, Aleid H, Broering D, Alqahtani S. Treatment with Grazoprevir/Elbasvir in Post-kidney Transplant Patients with Hepatitis C Virus Genotype 4 Infection. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.110260] [Reference Citation Analysis]
17 Lin S, Wang M, Liu Y, Huang J, Wu Y, Zhu Y, Wang X. Concurrence of HBV infection and non-alcoholic fatty liver disease is associated with higher prevalence of chronic kidney disease. Clin Res Hepatol Gastroenterol. 2021;45:101483. [PMID: 32646847 DOI: 10.1016/j.clinre.2020.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Hsieh MH, Bair MJ, Tsai PC, Tseng KC, Lo CC, Chen CY, Kuo HT, Hung CH, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL; T-COACH investigators. Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. J Gastroenterol Hepatol 2021;36:2247-54. [PMID: 33624849 DOI: 10.1111/jgh.15469] [Reference Citation Analysis]
19 Nevola R, Rinaldi L, Zeni L, Sasso FC, Pafundi PC, Guerrera B, Marrone A, Giordano M, Adinolfi LE. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. JGH Open. 2020;4:713-721. [PMID: 32782961 DOI: 10.1002/jgh3.12324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Taneja S, Duseja A, Mehta M, De A, Verma N, Premkumar M, Dhiman RK, Singh V, Singh MP, Ratho RK, Ramachandran R, Kumar V, Kohli HS. Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis. Liver Int. 2021;41:705-709. [PMID: 33025685 DOI: 10.1111/liv.14685] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
21 Jeon H, Kim JH, Lee SS, Kim HJ, Cha RR, Cho HC, Lee JM, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Impact of acute kidney injury on survival in patients with chronic hepatitis C: a retrospective cohort study. BMC Infect Dis 2021;21:301. [PMID: 33765952 DOI: 10.1186/s12879-021-05991-2] [Reference Citation Analysis]
22 Chuaypen N, Khlaiphuengsin A, Prasoppokakorn T, Susantitaphong P, Prasithsirikul W, Avihingsanon A, Tangkijvanich P, Praditpornsilpa K. Prevalence and genotype distribution of hepatitis C virus within hemodialysis units in Thailand: role of HCV core antigen in the assessment of viremia. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07074-2] [Reference Citation Analysis]
23 Lim JK. Management of Hepatitis C in Special Populations: HIV Coinfection, Renal Disease, and Decompensated Cirrhosis. Clin Liver Dis (Hoboken) 2020;16:29-31. [PMID: 32714521 DOI: 10.1002/cld.965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Fabrizi F, Cerutti R, Messa P. An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease. Pathogens 2021;10:1381. [PMID: 34832537 DOI: 10.3390/pathogens10111381] [Reference Citation Analysis]
25 Khan MU, Mahmoud MI, Butt AA. Hepatitis c virus and chronic kidney disease. Expert Rev Gastroenterol Hepatol 2020;14:579-90. [PMID: 32613874 DOI: 10.1080/17474124.2020.1776111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Cooper CL, Galanakis C, Donelle J, Kwong J, Boyd R, Boucher L, Kendall CE. HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study. BMC Infect Dis 2019;19:712. [PMID: 31438873 DOI: 10.1186/s12879-019-4315-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
27 Liu Y, Zou X, Chen W, Gong C, Ling L. Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study. Int J Environ Res Public Health 2019;16:E4436. [PMID: 31726750 DOI: 10.3390/ijerph16224436] [Reference Citation Analysis]
28 Chen YC, Li CH, Ko PH, Lee CC, Syu RJ, Tseng CW, Tseng KC. Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals. PLoS One 2021;16:e0256505. [PMID: 34437608 DOI: 10.1371/journal.pone.0256505] [Reference Citation Analysis]